Napsrx Test Questions and Answers 2024, Exams of Nursing

Download Napsrx Test Questions and Answers 2024 and more Exams Nursing in PDF only on Docsity!

icellsiandipromote iwhite ibloodicelliproduction. … irequire ithat ithe ipatient ifirst i undergo ichemotherapy ior i radiation ito ikill ithe idiseasedistem

Napsrx Test Questions and Answers 2024

1. Howiare idrugsisortediintoitherapeuticigroupsiandiclasses? A. firstiby itheiconditionsithatithey iare iuseditoitreat,ianditheniby itheirimechanismsiofiaction B. firstibyitheirimechanismsiofiaction,ianditheniby itheiritherapeuticieffects C. firstibyitheirisideieffects,iandithenibyitherapeuticieffects D.firstibyitheiritoxically,iandithenibyitheirieffectivenes s i2.Bone imarrowitransplants… A. B. …iareiaitypeiofistemicellitherapy,iunlessipatient’siownicellsiareireinjected. C. …iare ialwaysiaitypeiofistemicellitherapy. D. … ican ihelp ipeople iwith ileukemia, ia icondition iin iwhich ithe ibody idoes inot iproduce ienough i whiteblooi dicells.
2. WhatidoesiAMA istandifor? C.iAmericaniMedicaliAssociation
3. What i section i of i a i drug’s i package i insert i describes i situations i in i which i the i drug i should i not i be i usedbei cause ithe irisksioutweighitheitherapeuticibenefits? B. icontraindications i5.Whatiisitertiaryicare? B. i highly i specialized i medical i and i surgical i care i provided i by i a i large i medical i center i for i unusual i orcomi pleximedical iproblems
4. WhichiofitheifollowingiisiNOTioneiofitheistagesiinitheiclassic iapproach ito ibrandidevelopmentistrategy ic overediiniyourimanual? C. ibrandiquality
5. Whatiareivasodilatorsiuseditoido?

A.

B. mimicipathogensitoistimulateitheiimmuneisystem C. narrow itheibloodivessels D. stimulateitheiCNSitoimakeitheiheartibeatifaster decreaseivasculariresistance iandiincreaseibloodiflow

8. What iis ithe iname iof ithe icondition ithat ioccurs iafter ia ispecific idose iof ia idrug iis igiven iat isuch iregular iintervals ithat iabsorption iand ielimination i(and itherefore idrug iplasma iconcentration) ihave ibecome iconstant? A. homeostasis B. C. titration D. tolerance
9. WhichistatementiisiTRUEiaboutioculariadministration? A. Oculariadministrationiisiprimarilyiforidrugsithatimusticrossitheiblood-brainibarrier. B. C. Oculariadministrationiisiusediwheniaidrugimustienterithe ibloodstreamiimmediately. D.Oculariadministrationiisiusediwheniaidrug imustiproduceiimmediate ieffectsionithe ibrainiorispinal icord.
10. Whichientity/entitiesiinvest(s)ithe imostimoneyiinipharmaceuticaliR&D? A. Canadianipharmaceuticalicompanies B. theiNIH C. theiU.S. iGovernment D. i11.How iare imostidrugsiexcreted? A. viaitheibloodstream B. viaitheiheart C. viaitheikidneys D. viaitheiskin 12.Overithe ilastifew idecades,iwhatihasihappeneditoilegalilimitationsion isales’irepsidiscussionsiabout ioff ilabel iuses? A. Limitationsihaveidecreased. B. Limitationsihaveiincreasedisignificantly. C. Limitationsihaveiincreasedislightly. D. Limitationsihaveiremainediaboutitheisame.
11. According itoiyourimanual,iwhichiofitheifollowingiisianiexampleiofiaibrandingifundamental? U.S.ipharmaceuticalicompanies Oculariadministrationiisiusediprimarilyitoitreatitheieye.’ steadyistate

A. theibrandilogo B. theibrandiname C. theibrandipackaging D. theibrandipromise

14. Whatidoesiitimeaniifitwo idrugsiareiatiparity? A. Bothidrugsiare iessentially iiniaineutraliposition. B. Bothidrugsiare igenerics. C. Bothidrugsihaveiexclusiveipreferredistatus. D. Theitwoidrugsiare ibioequivalent.
15. Whoiisimostilikelyitoibenefitifromielectronicisamplingiprograms? A. Everyoneiwouldibenefitiequallyifromielectronicisamplingiprograms B. physiciansiinihospitalsiwhoiareitooibusyitoiseeirepresentatives C. physiciansiiniruraliareasiwhoiareinotiasifrequentlyivisitedibyirepresentatives D.physicians iin iurbaniareasiwho iare itoo ibusy ito isee irepresentatives i16.Whenireferringitoimedicationidosage,iwhichiabbreviationimeansi“one-half”: D. iSS
16. Whatiisianiinternist? A.iaiphysician iwhoipractices iinternal imedicine i18.Whichiofitheifollowing iisiaitypeiofiwhiteibloodicells? C.ilymphocytes
17. Whyiareinoviceisalesirepresentativesiofteniplacediinic hargeiofinegotiatingiMCOiformularies? A. toibecome imoreifamiliariwithithe ihealthcareiindustry B. toibecomeimoreifamiliariwithitheiriterritories C. P&Ticommitteesiareimoreireceptiveitoinewiface s. D.Theyiare inot. iThis ijobiisiusually ireservedifor imoreiexperiencedireps. i20.Whatidistinguishesipharmacodynamicsifromipharmacokinetics? A. Pharmacodynamicsistudiesiaidrug’siexivivoieffects. B. Pharmacodynamicsistudiesihowidrugsiaffectitheibody. C. Pharmacodynamicsistudiesitheibodyiaffectsidrugs.

D. Pharmacodynamicsistudiesitheitimeirequirediforiaidrug’siabsorption.

21. Whatiproportioniofitheidrugsitestedionihumanisubjectsiare ieventually iapprovediby iFDA? A. abouti20% B. abouti60% C. abouti70% D. abouti95% 22.According ito ia istudy idiscussediin iyour imanual, ihow ido imost i physicians iprefer ito ireceive itheir i drugsami ples? A. byiborrowingithem ifromihospitals B. byiorderingithemioveritheiInternet C. byitradingithem iforiservices D. directlyifromisalesirepresentatives
22. Whichiofitheifollowingiisianiexampleiofiaicentral ivalue? A. Iibuy iAdvilitoishow ithatiI’mimoderniconsumer. B. I ilike iAdvilibecause iweiwereibothiborniinithe i80s. C. IipreferiAdvilibecauseiIilikeitheiflavor. D. IipreferiAdvilibecauseiit’sieasieritoiswallow.
23. WhichiofitheifollowingispecialtiesilikelyihasitheiMOSTiemergencyicalls? A. cardiology B. psychiatry C. urology D.Allispecialistsihaveithe isameinumberiofiemergency icalls. i25.Whatiaffectsithe irateiofiactive itransport? A. theiavailability ioficarriers,ibutinotienergy B. theiavailabilityiofienergy,ibutinoticarriers C. theiavailability ioficarriersiandienergy D. neitheritheiavailabilityioficarriers,inoritheiavailabilityiene rgy
24. Overithe ilastifew idecades,iwhatihasihappeneditoitheiFDA iapproval itimeiforinewidrugs? A. Itihasibeenilengtheneditoiensure isaferidrug iproducts.

B. ItihasibeenilengtheneditoilimitiDTCimarketing. C. Itihasibeenishorteneditoiimproveidrugiquality. D.Itihasibeenishorteneditoireduce itheicostiofinew idrugidevelopment. i27.Whichiof itheifollowingiwouldiNOT ihelpiimproveicompliance? E. patientsilikingitheiriproviders F. patientsiusing ionlyioneipharmacist G. pharmacistsiunderstandingihowigenericsidifferifromibrandinamesidr ugs H. supportigroups

28. Whichientityichoosesiaidrug’sitrade iname? A. theidrug’siinventor B. theidrug’simanufacturer C. theiFDA D. theiUnitediStatesiPharmaceuticaliCouncil
29. Whatitypeiofistemicellsiareiobtainedifrom iembryosiandicanidevelopiintoianyicellitype? A. multipotent B. pluripotent C. totipotent D. Allistem icellsicanidevelopiintoianyicellitype.
30. As i the i price i a i patient i pays i for i a i prescription i increases, i what i happens i to i the i likelihood i that i thepai tientiwillifill iit? A. Itidecreases. B. Itiincreases. C. Itiremainsiunaffectedibecauseitheiprescriptioniisineeded. D.Itiremainsiunaffectedibecauseitheiprescription’siincreasedicostiisioffsetibyiitsiperceivedivalue. i31.Most iinvoluntary imovementsicome ifrom iwhichitypeiofimuscle itissue? A. cardiaciandismooth B. onlyiskeletal C. skeletaliandicardiac D. skeletaliandismooth

32. WhichiofitheifollowingiisiNOTione iofitheibody’simajoriorganisystems? A. theicardiovascularisystem B. theicellularisystem C. theigastrointestinalisystem D. theimusculoskeletalisystem
33. Howidoimostidrugsiexertitheiriprimaryiphysiologicalieffects? A. byiactivatingisynapsesibetweenidifferentitypesiofitissues B. byibindingitoicellireceptorsithatiare isensitiveitoitheiripresence C. byiinhibitingisynapsesibetweenidifferentitypesiofitissues D. throughigeneticimutation
34. What i is i the i most i reliable i source i of i information i for i determining i therapeutically i equivalent i drugpri oduct? A. AMAiguide B. BlueiBook C. FDAidrugilist D. Orange iBook
35. Whatidoesisubcutaneousimean? C. ibeneathitheiouteriskin
36. Whatishouldiaisalesirepresentativ e idoiifiall iofitheiprimeispacesiiniaidrugicabi netiare icoccupied? A. askistaffiforipermissionitoim ove isomeiofitheiotheriproductsi inithe icabinet B. askistaffiforipermissionitoith rowiawayiexpirediproductsii nitheicabinet C. askithe idoctor iifihe istill ineedsisome iofitheiotheriproductsiinithe icabinet D. surreptitiouslyimoveiyourila rgesticompetitor’siproductsi outiofitheiway
37. It i is i inappropriate i for i

B. positive C. potent D. primary

39. Whatiareithei 2 ilegaliclassificationsipfiwholesalers? A. distributorsiandisupplyichains B. pharmacistsiandiNAMs C. primaryiandisecondaryiwholesaleidistributors D. retailersiandiinstitutions 40.Whatiterm idescribesitheiusageiofiaimedicationiforipurposesiotherithanitheiFDA-approvediindications io n ithe ilabeling? A. contraindicativeiindication B. off-indicationiusage C. off-labeliusage D. secondaryiindication
40. Whatiisitheiacronymipharmacokinetics? C. iPK
41. Theidosage irangeiofiaidrugithatiisibothisafeiandiben eficialiknowniasithe itherapeuticiwindow. A. True B. False
42. Whatiisitypically iNOTiaicharacteristiciofiaipharmaceuticali salesirep? A. Pharmaceuticalisalesirepsiareiauthenticiandireal B. Pharmaceuticalisalesirepsiareicreative C. Pharmaceuticalisalesirepiareifocused. D. Pharmaceuticalisalesirepiareinoticoncernediabou ticompetitors.
43. Whatientityigrantsidrugipatents? A. theiFDA B.theiFDAiifitheidrug iis iover-the-counter iandithe iU.S. iPatentiandiTrademark iOffice iif ithe idrugiis iprescription C.theiFDAiofitheidrugiisiprescriptioniandithe iU.S. iPatentiandiTrademark iOffice iifitheidrugiisiover- ithe i-counter

D. theiU.S.iPatentiandiTrademarkiOffice

45. Which i of i the i following i refers i to i all i active i and i inert i pharmaceutical i ingredients i in i a i drug, i includingfi illers iandicolors? A. formulation B. mycoplasma C. peptide D. saccharide
46. Whatiisitheidifferenceibetweenipotencyiandiefficacy? A. Doctorsipreferimore ipotentidrugs. B. Drugsimanufacturersipreferimoreipotentidrugs. C. Potencyirefersitoitheidrug’sieffectiveness,iwhileiefficacyirefersitoiitsistrength. D.Potencyirefersitoitheidrug’sistrength,iwhileiefficacyirefersitoiitsieffectiveness . i47.Whatiisithe iminimumileveliofieducationirequirediforiainurse ipractitioner? A. aicertificationiprogram B. aniassociate’sidegree C. aibachelor’sidegree D. aigraduate idegree
47. Howimanyinamesimustiaidrugihave? A. atimostithree B. C. atimostifive D. atileastifive
48. Howihasiailongeridevelopmentitimeiincreaseditheicostiofibringingiainewidrug itoimarket? A. byidecreasingipatientiattrition B. byidecreasing itheicostioficapital C. byiincreasing itheicostioficapital D. byiincreasing itheinumberiofiproductirecalls
49. Senioricitizensiconsume iover timesiasimany ipharmaceuticalsiasipeopleiunderi65. A. three atileastithree

B. five C. ten D. fifteen

51. Whatiagency iregulatesitheidistributioniandiuseiofinarcotics? A. DEA B. FTC C. OIG D. TSA
52. Whatiisipassive idiffusion? A. aitypeiofipinocytosis B. membraneitransporti viaivesicles C. theiuse iofienergyitoihelpiaisu bstance ipassifrom iailowiconcentrationig radientitoiaihighione D.wheniaisubstance ifreely imovesithoroughiaimembrane ifrom ia ihighiconcentration igradient ito ia ilow ione
53. Whatiareithe iMAINicategoriesiofidrugsiunderiFDAijurisdiction? A. activeidrugsiandiactive iplacebos B. biopharmaceuticalsiandinutraceuticals C. non-prescriptioniandinutraceuticals D. prescriptioniandinon-prescription
54. Whichiofitheifollowingiisiainaturaliuterotoniciagent? A. hemoglobin B. leukotriene C. oxytocin D. VitaminiK
55. Whatiareiallimetabolites? A. activeisubstances B. inactiveisubstances C. injections D. productsiofimetabolism

56. Wheniaidrugiisiadministerediorally,iwhereidoesifirst-passimetabolismioccur? A. intestine B. liver C. pancreas D. stomach
57. Whatiisitheimedical itermiforiswelling? B. iedema
58. Whichiofitheifollowing iisiNOTipartiofithe iSeveniStepiCascade iofiEmotion? A. beiaiconsultant,inotiairep B. identifyiwhatiyouriproductidoes C. reflect D. visualize itheipoweriofi 10
59. Whichipartiofiaiclinicaliresearchipaperii sifrequentlyireferredito iasitheiroadimap? A. abstract B. findings C. letteritoitheieditor D. methods
60. Whichiofitheifollowingiisiaimainiactive iingredientiinilungisurfactants?

A.

B. germicides C. sympathomimeticidrugs D. theophylline

61. Whatidoesiparenteralimean? B. iinjections
62. Whichitermidenotesiaitype iofisubstance ithatienhancesitheiactioniofiai drugioriantigen? A. adjuvant B. indicated C. ligase D. peptide animalilungiextract

63.Ifiaisalesirepresentative’siproductiisiplacedionithe iseconditieriofistandardithree-tieriformulary, iwhich iof ithe ifollowing iisimostilikely itrue? A. itihasinotibeenireviewediby itheiP&Ticommittee. B. itiisiiniaineutralipositioniunless iitiisiatiparity iwith iotheridrugs. C. itiprobablyihasiexclusive ipreferredistatusiifiitinotiatiparity iwithianyiotheridrugs. D.it iwilliessentially isell iitself iif iit iis igranted iexclusiveipreferred istatus. i64.WhichiofitheifollowingiisiNOTione iofitheifouribasicitransportimechanisms? A. activeitransport B. homeostasis C. passiveidiffusion D. pinocytosis

65. Whichistatementiaccuratelyidescribesiairelationshipibetweenidrugiagonistsiandiantagonists? A. Agonistsiandiantagonistsicanibeiuseditogether. B. Agonistsiandiantagonistsishouldinotibeiuseditogether. C. Antagonistidrugsiactivateireceptors,iwhileiagonistsiblockiaccessitoireceptors. D. Antagonistsiareiendogenousiwhereasiagonistsiareiman-made.
66. Whatiisitheistudy iofitheieffectsiandimovementiofidrugsiinithe ihumanibody? C.iclinicalipharmacology 67.According ito iyour imanual, iwhat iis ia icommonicomplaintithatiphysicians ihave iaboutitraditional isampling imethods? A. thatidrugisampleisupply iisitooiunpredictable B. thatipatientsiareilessilikelyitoitakeifreeisamplesibecauseithey ithinkitheyiareiloweriquality C. thatipatientsidoinotilikeiseeingidrugirepresentativesiinitheirioffices D. thatitheyireceive itooimany idrugisamples 68.Which iof ithese ientities iis iformed iby itwo ior imore ihospitals ior iother ihealthcare ientities ito i negotiateredi ucedirates iwith iitsiaggregated ipurchasingipower? A. GPO B. In-stateiwholesaler C. PPO D. RPO

69. Whatiisianotherinameiforiaidrug iderivediaibiologicicompound? A. B. oligonucleotide C. organism D. smallimolecule
70. What iis i the i most icommon i policy i regarding i pharmaceutical i reps i dispensing i drug i samples iin ihospitals? A. Byifederalilaw,idrugisamplingiisipermittediiniallihospitals. B. Byifederalilaw,iitiisiupitoiindividualiphysicians,inotitheihospital. C. Drugisampling iisiencouraged,ibutinotirequired. D. Drugisamplingiisiofteniforbidden.
71. Whichiofitheifollowingiwouldihelpiyouibuilditrustiwithiaiphysician? A. askingiifiheiorisheiisihavingianyiproblemsiwithitheimanagedic are icoverageiofiyouriproducts B. repeatingiaiquestioniyouialreadyiasked C. surprisingitheiofficeistaffiwithiainew iposteriinitheibreakiroom D. Noneiofithese iwouldihelpiyouibuilditrustiwithiaiphysician. 72.What iterm idenotes ithe idifference ibetween ithe iusual ieffective idose iand idose ithat iinduces isevere ior ilife-threatening isideieffects? A. B. marginiofisafety C. theiplaceboieffect D. therapeuticiwindow
72. Whatiareiexcipients? A.a itype iof icell ireceptor ito iwhichiantagonists ibindito idecrease ithe ieffects iof ithe ibody’s inatural iagonists B. anotheriterm igenericiequivalents C. sitesiofiactionibesidesitheitargetisitesiofiaction D.
73. Whatiisianotheriterm ifor itheiAWP? A. dock-to-dockiprice theiinertiingredientsiiniaidrug iformulation dose-responseirelationship largeimolecule

B. floatiprice C. D. non-stockiprice

75. Whichiofitheseiisitheimostilikelyiuse iforiaiuterotoniciagent? A. B. toimakeitheiurineimoreialkaline C. toisupplementioralifoodiintake D. toitreatihyperthyroidism
76. AsiofiNovemberi2013,iwhichiofitheseicountriesihasilegalizediDTC iadvertisingiofiprescriptionidrugs? A. Canada B. Japan C. Spain D.
77. Whyiareioralidrugsioftenitakenioniemptyistomach? A. toibeimoreiwhollyiabsorbedibyistomach B. toiminimizeiabsorptionibyiintestine C. toiminimizeinausea D. toipassithroughitheistomachimore iquickly
78. Whatiisioneifactorithatidifferentiatesicommunityihealthicentersifromihospitals? A. Communityihealthicenteriformulariesiareimoreirestrictive B. Communityihealthicentersihaveihigherireimbursementirates C. Neweribrandinameidrugsiare ieasieritoiaccessiaticommunity ihealthicenters. D. noneiofithese
79. Howidoesisamplingiprovideiaisocial ibenefit? A. Doctorsidonateitheiriunusedidrugisamplesitoicharities. B. Doctorsiofteniuseidrugsisamplesitoitreatipatientsiwhoiotherwiseicouldinotiaffordiit. C. Itiallowsipatientsitoitryioutidifferentiprescriptionimedicationsibefore iconsultingiwithiphysicians. D. Drugisamplingiprovidesiaisocialibenefitiinialliofitheseiways.
80. Whichimedical itermidenotesithe iuse iofiaistethoscopeitoilistenitoithe iheart? noneiofithese toiinduce ilabor listiprice

A. auscultation B. cardioversion C. catheterization D. echocardiography i81.Whatidoientericicoatingsido? A. facilitateivomiting B. helpidrugsidissolve iinistomach C. helpidrugsienteritheibloodstreamimoreiquickly D.

82. Whatiisitheidurationiofiexclusivityiforiorphanidrugs? A. 6 imonths B. 1 iyear C. 7 iyears D. 15 iyears
83. WhatidoiNationaliAccountiManagersido? A. actiasitheisalesireps’iprimary ipointioficontactiwithitheirestiofitheicorporation B. manageitheiFDAiapprovaliprocess C. negotiate icontractsiwithiMCOsiandiPBMs D. sellionlyitoipharmacies
84. Whatidoesiitiusually imeaniifiaidrug irecalliisivoluntary? A. Pharmaciesimayichoose iwhetheritoireturnithe idrugioridispenseiit. B. TheiFDAihasideterminedithatitheidrugiisiperfectlyisafe,ibutiineffective. C. The i manufacturer i has i recalled i the i product i on i its i own, i but i negotiated i with i the i FDA beforehand. D.Theimanufacturerihasirecallithe iproductiwithoutinegotiatingiwithitheiFDA. i85.Whichiphaseiof iclinical itrialsiisialsoiknowniasitheipivotal iphase? A. Phase iI B. Phase iIII C. Phase iIV preventidissolutioniinitheistomach

D. Phase iIX 86.Duringiwhichiphase ioficlinical itrialsiisitheinewidrug’sisafety iandieffectivenessifirstitestediinithe itarget igroup? A. preclinical B. Phase iI C. Phase iII D. Phase i III i87.Howidoiantacidsiwork? A. byiincreasingibloodiflowitoithe istomach B. byiloweringigastricipH C. D. byisuppressingicholesteroliformationibyitheiliver

88. Whatiisione iofitheibiggestitimeiwastersiforiaipharmaceutical isalesirep? A. caterers B. pharmacists C. receptionists D.
89. Whatihappensiwheniequilibrium iisireached? A. equalinumbersiofimolecules icrossitheimembraneiinibothidirections B. moleculesistopimoving C. theiconcentrationigradientidecreasesiindefinitely D.theiconcentration igradient iincreasesiindefinitely i90.Whatiare itheimosticommonivectorsiusediinigeneitherapy? A. autologousiantigens B. liposomes C. nakediDNA D. viruses
90. Whatiisitheipercentageifee ithatitheidispenseripaysitheiwholesaleriforidistribution? A. marginifee travelitime byiraisingigastricipH

B. recharge C. standardifee D. upcharge

92. Whatiisitheidifferenceibetweeniaichronici(oricontinuing)ireaction,iandiaidelayedireaction? A. Chronicireactionsiareiexaggerated,iwhereasidelayedireactionsiareiidiosyncratic. B.Chronici reactions ioccur ionly iduring itreatment, iwhereas idelayed i reactions ionly ioccur iduringwi ithdrawal. C. Chronicireactionsipersistiforiailongitime,iwhereasidelayedireactionsitakeisomeitimeitoidevel op. D.Delayedireactionsiareialwaysiidiosyncratic,ibutichronicireactionino t. i93.Whatiisiclinicalieffect? A. federallyifundediresearchicondition B. theieffectiofimaximumidosage C. D. theiuse iof itreatmentidrugs iin ichemotherapy i94.Whichiofitheifollowingiisianiexampleiofinoncompliance? A. aipatientiforgettingitoitakeiaidrugiatiaispecifieditime iaiday B. aipatientitaking iaidrug,ibutionlyibecause iitihasibeenicourt-mandated C. aipharmacistidispensingiaigenericiequivalentiofiaidrugiinsteadiofitheibrandiname D. aiphysicianirefusingitoiprescribe iaidrugibecause i(s)he idoesinotitrustithe iclinical istudiesioniit i95.Whatiisithe iaverage icirculationitime iofiblood? A. aboutiaiminute B. abouti 5 iminutes C. abouti 5 itoi 10 iminutesidependingionitheipatient’siage iandihealthiconditions D. abouti 10 iminutes
93. Whatiisioneiway iiniwhichipharmaceuticalisellingiisidifferentifromiselling iinimostiotheriindustries? A. in i pharmaceutical i sales, i the i decisions-makers, i consumers, i and i payers i are i usually i the i same entity B. Pharmaceuticalisellingitakesilessitimeibecauseidoctorsiareisoibusy. C. RepresentativesidoiNOTisellithe iendiuseriofitheiproduct. D. RepresentativesiDOisellito itheiendiuseriofitheiproduct. theiresponseiproducedibyiaimedication

97. From iwhatitypesiofientitiesidoiprimary iwholesaleidistributorsibuy imostiofitheiridrugs? A. brokerages B. buying iclubs C. manufacturers D. physicians
98. WhatiisitheiOffice iofitheiInspectoriGenerali(OIG)? A. aidepartmentiinipharmaceuticalicompanies B. C. aniarm iof itheiEuropeaniMedicinesiAgency D. aniarm iofitheiFDA
99. Whatiareidoctorsirequireditoiconsideriwhenideciding iwhetheriorinotiprescribeiaiparticularidrug? A. quantity iofilifeioveriquality iofilife B. thatinoidrugsiwithiadverseieffectsishouldieveribeiused C. theiinferiorityiofiOTCidrugs D.theiseverityiofitheidisorderibeingitreatediandithe ieffectiitihasionitheipatient’siqualityiofilife i100.Which ientityiassignsiainew idrugiits igenericinames? A. theidrug’siinventor B. TheiFoodiandiDrugiAdministration C. D. theiUnitediStatesiPharmaceuticaliCouncil
100. Drugsican ibeiused daysibeyonditheiriexpirationidate. A. 2- 7 idays,idependingionithe imosticurrentimonograph B. 2- 90 idays,idependingionistate ilaws C. 7- 90 idays,idepending ionitheitypeiofidrugiandiitsitherapeuticiclass D. noneiofithese
101. Whatiisinecessaryiforiaidrugito ibeiexcretediextensively iviaitheikidneys? A. Theidrugimustibeiwater-soluble, iandinotibinditooitightly itoiproteinsiinitheibloodstream. B. Theidrugimustihave iaiphospholipidibilayeriandibeinon-water-soluble. C. Theidrugimustihaveiaiphospholipidibilayeriandibindiwellitoiproteinsiinitheibloodstream. theiUnitediStatesiAdoptediNameiCouncil aniarm iofitheiDepartment iofiHealthiandiHumaniServices

D. Theidrugimustinotibeiwater-soluble.

103. Whichiorganizationioriindividual iinitiatesitheiclinical itrialiandifinancesitheistudy? A. clinicaliresearchiorganization B. investigator C. researcher D. sponsor
104. The nameidescribesitheiatomiciorimolecularistructureiofiaidrug. A. chemical B. generic C. pharmaceutical D. proprietary
105. Under i PhRMA i Code, i is i it i acceptable i or i unacceptable i for i a i pharmaceutical i sales i rep i to i take i ap hi ysicianianditheiphysician’s ispouseito iaifundraising idinner? A. acceptable iifionlyitheiphysicianiattends B. acceptable iifionlyitheiphysicianiattends,iandithe itotal iisiunderi$ C. acceptable iifitheitotal iisiunderi$ D. unacceptable
106. The i Hatch-Waxman i Act i is i considered i the i most i significant i drug-related affecting i the ipharmaceutical iindustry isince i1962. A. experiment B. legislation C. process D. research
107. What i term i denotes i the iextent, i quality, i or idegree i to iwhich i a i substance iis i poisonous ior i harmful i toithe ibody? A. caliber B. chronicity C. indication D. toxicity
108. WhatiissueihasiMOSTiencouragediconsumers’idesireitoisee imoreiOTCimedications?

A. aiweakeripatients’irightsimovement B. lackiofiinsuranceicoverage C. lessireliance ionitheiInternet D. proliferationiofiherbaliremedies

109. Whatiisitheidegreeitoiwhichiaimedicationiproducesiaitherapeuticieffect? A. diffusion B. efficacy C. protease D. vector
110. Whatiisitheimostiimportantibenefitiofielectroniciprescribing? A. choice B. cost C. inquiries D. safety
111. WhenidoesitheiFDAiregulateigenericidrugs? A. onlyiifitheyiare ibrandedigenerics B. onlyiifitheyihaveibeenicontested C. always D. never
112. Whichiphase iofitrialsilargely ideterminesitheiclinical idose? A. preclinicalitrials B. Phase iIIitrials C. Phase iIII itrials D. Phase iIVitrials
113. Whatiisianiadvantageiofiinactivatedivaccinesioveriattenuatedivaccines? A. Inactivatedivaccinesiareilessiexpensiveitoiprepare. B. Inactivatedivaccinesihaveiaihigheriprobabilityiofieliciting itheidesirediimmunologicaliresponse. C. Inactivatedivaccinesihaveiaimoreistableishelfilife. D. Inactivatedivaccinesionlyirequireiaisingleidose.

114. Whichimedical itermidenotesiailow isupply iofioxygenidueitoibloodiflow? A. potentiation B. ischemia C. TID D. titration
115. Whatiareithe itwoimainiofiprescriptionidrugimarketing? A. (1) imarketingitoiinsurance icompanies,iandi(2)imarketingitoipharmacies B. (1)iPBMimarketing,iandi(2) imarketingitoigovernments C. (1)iprofessionaliphysicianipromotions,iandi(2)idirect-to-consumeriadvertising D.(1)ipublicly-fundedimarketing,iandi(2)iphysician- fundedimarketing i116.Whatiis itheisiteiofideliveryiforisubcutaneousiinjections? A. fatty itissueibeneathitheisurface iofitheiskin B. lymphaticitissue C. muscle itissue D. theistomach,iviaiaispecial itypeiofineedle
116. Whatimustibe icontainediinitheiDescriptionisectioniofiaipharmaceutical ipackageiinsert? A. adverseieffects B. mechanismiofiaction C. pharmacokinetics D. theiproprietaryinameiandiestablishediname
117. Whatiisitheistudy iofiaimediation’sieffectsiasiitithroughithe ibody? A. pharmacodynamics B. pharmacogenetics C. pharmacogenomics D. pharmacokinetics
118. Customersipurchase iproductsifrom ipeopleitheyilike,itrust,iandirespect. i Thisiisicalledithe . A. closingiofitheisale B. firstitimeiadvantage C. likeabilityifactor

D. poweriofiknowledge

120. Whatiisipenicillin’simechanismiofiaction? A. Itidisturbsibacterialicelliwallisynthesis. B. Itiinhibitsithe iproductioniofiviruses. C. ItipreventsiproperiDNAireplication. D. Itisendsiaimessengeritoithe iboneimarrowitoiproduceiextraiwhite ibloodicells. 121.According ito iyour i manual, ihow ihas ithe iU.S. ihealthcareimarketplaceichangediinitheilastifew idecades? A. FeweriandifeweriprescriptionidrugsihaveibeenimadeiavailableiasiOTCs. B. Managedicareihasibeeniincreasinglyireplacedibyimoreipatient-centerediapproaches. C. TheiagingiBabyiBoomerigenerationihasibegunidemanding imoreipersonalizediattention. D.Thereihas ibeenidecreasediemphasis ionipreventiveihealth. i122.Howidoesipharmaceuticalimarketingihelpinarrowitheitreatmentigap? A. Itiencouragesipatientsitoitakeimoreiactiveirolesiinitheirihealthcare . B. Itimakesidoctorsimoreiskepticaliofitheipharmaceuticaliindustry. C. Itimakesipatientsimoreiskepticaliofitheiridoctors’iopinions. D. all iofithose
121. Whatidoiimmunosuppressiveiagentsido? A. decreaseiriskiofiinfection B. increaseiriskiofiinfection C. increaseithe iriskiofirejectioniofiforeignibodies D. treatedipsoriasis
122. WhatitypesiofidrugsiareiEGFRiinhibitors? A. antineoplastics B. cardiovasculariagents C. CNSiagents D. mitoticiinhibitors
123. Whichiofitheifollowing imeansioutside iofitheiliving ibody? A. enivivo

B. exivitro C. exivivo D. intraivivo

126. The i FDA i requirements i for i nutraceuticals i and i medicinal i herbs i are i just i as i stringent i as i for ipharmaceuticals. A. True B. False
127. What i is i the i estimated i net i gain i of i private-sector i healthcare’s i contributions i to i increased i U.S. i lifeei xpectancy? A. $5- 10 ibillion B. $40- 50 ibillion C. $800- 900 ibillion D. $2- 5 itrillion
128. WhichistatementiisiTRUEiregardingipost-approvalidrugimonitoring? A. Alliside ieffectsiareideterminediduringiclinicalitrials B. Drug i manufacturers i are i only i required i to i report i adverse i effects i if i they i are i severe i or i life-threai tening. C.Drug imanufacturers iare i only i required i to i report i adverse ieffects iif ithey ihave i been iproven i inci linicalistudies. D. TheiFDAicanichoose itoiwithdrawitheiriapprovaliifinewievidence iarises.
129. Which i term i denotes i when i tolerance i to i one i medication i causes i increased i tolerance i to i anothermi edication? A. cellitolerance B. cross-tolerance C. indicateditolerance D. minimizeditolerance
130. Patentsiexpire yearsifromithe idateiofifiling. A. ten B. fifteen C. twenty D. thirty

131. Afteriaitrade-nameidrug’sipatentiexpires,ihowimayigenericiversionsiofiitibeisold? A. onlyiunderithe ibrandedigenericiname B. onlyiunderithe igenericiname C. onlyiunderithe ioriginal itrade iname D. underithe ioriginal itrade inameiorigenericiname
132. Whatiisirequirediforiainewipharmaceuticalito ibeiconsiderediaiviableitherapy? A. Iticausesinoiseriousiadverseieffects B. Iticausesinoisideieffects. C. Itihasianiactive iplacebo. D. It i is imore i effective i and/or i causes i fewer i serious i adverse i effects i than i other i drugs i on i the market.
133. Underithe iAMAiguidelines, iwhoiisiultimatelyiresponsible iforiminimizingiconflictsiofiinterest? A. doctors B. lawyersiandiofficeimanagers C. pharmaceuticalicompanies D. salesirepresentatives
134. Theiactiofidispensingiaipharmaceutical ialternativeiforithe iproductiprescribediis. A. alternative ilicensure B. equivalenceipractice C. necessitatedisubstitution D. pharmaceuticalisubstitution
135. skipped
136. Whichiofitheifollowingiisitheicorrectimedicaliacronymiforieffectiveidose? A. DE B. ED C. EFD D. effiD
137. Whyiisioneigroupiofisubjectsigivenianiactive idrug,iwhileianotherigroupionly ireceivesiaiplacebo? A. toiassessipatients’iexpectations

B. toiassessitheidrug’sieffectiveness C. toiassessitheiprofessionalismiofitheistudyistaff D. toiassess itheisubjects’idemographics

138. A i generic i version i is i likely i to i have i some i inactive i ingredients i that i are i different i from i those i of i theori iginalidrug. A. True B. False
139. Whichiofitheifollowing iisianiexample iofiaifunctionalivalue? A. I idrinkiCoca-Colaibecause iIiamiaicitizeniofitheiworld. B. IidrinkiCoca-ColaibecauseiIilikeilookingilikeiaitraditionalist. C. I idrinkiCoca-ColaibecauseiIilike itheitaste. D.I idrinkiCoca-Colaibecause iitiisianiinternationalibrand. i140.Whereiareimostidrugsimetabolized? A. interstitialispaces B. liver C. stomach D. theibloodstream
140. Whatiisiessentialitoitheiethicalirequirementithatisubjectsi be iselectedifairly? A. Selectionicriteriaishouldibeiwell-supportediby idocumentedievidence. B.Studies ishould imake ievery iattempt ito iconduct i research ion isubjects iwhoiare iunderprivileged andiinineediofimedical iattention. C. Subjectsishouldibe iselectedibasedioniscientificiobjectives. D. all iofithese
141. Which i of i the i following i is i the i most i appropriate i salutation i for i a i cover i letter i if i you i cannot i find i acontaci t iname? A. DeariPersonneliDepartment B. DeariSirioriMadam, C. DeariSir, D. ToiWhomiItiMay iConcern,
142. Whatiisipartiofibecoming ianiindispensable ipharmaceutical isalesirep?

A. askingiforifeedback B. givingitheidoctorsianything itheyiaskiforitoiprescribeiyouriproducts C. keepingiyourimarketishare igoalsitheisameieachiterm D. notibothering ibusyidoctorsiinihospitals 144.Which iofithe ifollowing iis iNOTitypically iincluded iin ithe iindications iandiusageisection iof ithe ipackage iinsert iinformation? A. diseasesioriconditionsithatithe idrugsiisiapproveditoitreat B. theidrug’siactiveimetabolites C. theidrug’sirecommendediusualidosage D. theidrug’siusualidosageirange 145.Whichitermidenotes ithe ipractice ioficlassifying iphysicians iandiother ipotential iprescribersiby ianticipated iprescriptionivolume? A. conditioning B. deciling C. detailing D. privateilabeling

146. Whatimakesiaidrugieligibleiforifastitrackiapprovalifromithe iFDA? A. Itiisiaigenericithat ihasialready ibeeniapprovediasiaibrandedidrug. B. It iisiainew idrug. C. Itiisilessiexpensive ithaniwhatiisicurrently ionitheimarket. D. Ititreatsipatientsiwithiaiserious,ilife-threateningicondition. 147.Initheigastrointestinal itract, helpibreakiup itabletsitoiensure ifull irelease iof ithe iactive ipharmaceutical iingredient. A. binders B. disintegrants C. dispersingiagents D. lubricants
147. According itoiyourimanual,iwhatidoesithe iPDRPido? A. Itieducatesipatientsionitheiritreatmentioptions. B. Itiexpandsisalesirepresentatives’iaccessitoipatienti information.